Last reviewed · How we verify
Placebo domperidone
Domperidone is a dopamine antagonist that blocks dopamine receptors in the chemoreceptor trigger zone to reduce nausea and vomiting while promoting gastric motility.
Domperidone is a dopamine antagonist that blocks dopamine receptors in the chemoreceptor trigger zone to reduce nausea and vomiting while promoting gastric motility. Used for Nausea and vomiting, Gastric dysmotility and delayed gastric emptying, Functional dyspepsia.
At a glance
| Generic name | Placebo domperidone |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Dopamine antagonist / Prokinetic agent |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Domperidone acts as a peripheral dopamine D2 receptor antagonist that does not cross the blood-brain barrier significantly, making it selective for gastrointestinal effects. It increases gastric contractions and accelerates gastric emptying while suppressing the vomiting center through action on the chemoreceptor trigger zone. This dual mechanism makes it effective for treating nausea, vomiting, and gastric dysmotility.
Approved indications
- Nausea and vomiting
- Gastric dysmotility and delayed gastric emptying
- Functional dyspepsia
Common side effects
- Headache
- Abdominal cramps
- Diarrhea
- Dry mouth
- Hyperprolactinemia (rare)
Key clinical trials
- Efficacy of Domperidone (a Prokinetic Agent) on Time in Range in Digestively Asymptomatic Type I Diabetic Patients With Delayed Gastric Emptying (Gastro-TIR) (PHASE3)
- Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Participants With Functional Dyspepsia (PHASE4)
- REALITY MONITORING (NA)
- Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants (PHASE1)
- Emotions, Dopamine, Brain and Body (PHASE4)
- Efficacy of ASIMOMMY® Compared to Domperidone and Placebo in Increasing Breastfeeding: Randomized Single-Blind Controlled Trial in Indonesia (PHASE2)
- Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy (NA)
- A Scintigraphy Study in Adults With Diabetic Gastroparesis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |